시스플라틴을 이용한 경동맥 화학색전술 후 발생한 용혈성 요독증후군

Hemolytic uremic syndrome (HUS) is a rare disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. These characteristics are related to the formation of platelet-rich microthrombi in the microvasculature. HUS is associated with a variety of etiologies,...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of medicine Vol. 85; no. 1; pp. 67 - 72
Main Authors 양지은, Jee Eun Yang, 김강모, Kang Mo Kim, 심주현, Ju Hyun Shim, 임영석, Young Suk Lim, 이한주, Han Chu Lee, 정영화, Young Hwa Chung, 이영상, Yung Sang Leef
Format Journal Article
LanguageKorean
Published 대한내과학회 01.07.2013
Subjects
Chemoembolization
Cisplatin
Hemolytic uremic syndrome
Therapeutic
시스플라틴
용혈성 요독증후군
화학색전술
Online AccessGet full text

Cover

More Information
Summary:Hemolytic uremic syndrome (HUS) is a rare disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. These characteristics are related to the formation of platelet-rich microthrombi in the microvasculature. HUS is associated with a variety of etiologies, including cisplatin. Previously reported HUS cases after cisplatin administration were almost always related to systemic combination chemotherapy that included cisplatin. Transarterial chemoembolization (TACE) is commonly used in treatment of hepatocellular carcinoma, and most centers in Korea use cisplatin. A 70-year-old female with hepatocellular carcinoma was treated with TACE including cisplatin and subsequently developed clinical and laboratory findings compatible with HUS. (Korean J Med 2013;85:67-72)
Bibliography:The Korean Association Of Internal Medicine
ISSN:1738-9364